XML 28 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (17,565,866) $ (11,438,440)
Adjustments to reconcile net loss to net cash (used in) / provided by operating activities:    
Depreciation and amortization 2,401,628 2,022,029
Asset impairment charges 6,737,580
Loss on disposal of business 2,142,319
Increase in bad debt expense 665,973 363,512
Stock-based compensation 13,717,333 15,745,822
Amortization of debt issuance costs 210,737
Change in operating assets and liabilities, net of the effects of acquisitions:    
Accounts receivable (8,712,954) 2,281,773
Prepaid expenses and other assets (573,333) 2,650,951
Accounts payable (1,320,150) 943,171
Revenue share payable 1,515,262 (387,776)
Accrued expenses and other liabilities 1,305,164 (301,366)
Deferred tax liabilities (7,695,374)
Deferred revenue (67,472) (1,225,598)
NET CASH (USED IN) / PROVIDED BY OPERATING ACTIVITIES (7,239,153) 10,654,078
CASH FLOWS USED IN INVESTING ACTIVITIES:    
Purchases of property and equipment (87,073) (81,005)
Proceeds from sale of property and equipment 10,000
Cash paid for acquisitions, net of cash acquired (82,947,264) (2,000,000)
Proceeds from sale of business 2,540,000
Purchase of short-term investments (162,777,510) (55,931,821)
Redemptions of short-term investments 218,709,331
Capitalized software development costs and other (784,349) (163,560)
NET CASH USED IN INVESTING ACTIVITIES (25,336,865) (58,176,386)
CASH FLOWS (USED IN ) / PROVIDED BY FINANCING ACTIVITIES:    
Proceeds from long-term debt, net of issuance costs 37,730,000
Repayment of long-term debt (1,710,000)
Repurchase of common stock (7,522,426) (20,024,258)
Proceeds from exercise of stock options, net of cash paid for withholding taxes (277,785) 1,073,481
NET CASH PROVIDED BY/(USED IN) FINANCING ACTIVITIES 28,219,789 (18,950,777)
NET DECREASE IN CASH AND CASH EQUIVALENTS (4,356,229) (66,473,085)
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD 18,208,685 84,681,770
CASH AND CASH EQUIVALENTS – END OF PERIOD 13,852,456 18,208,685
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for interest 1,212,619
ROU assets obtained in exchange for lease obligations 459,580
Reduction of EvinceMed purchase price for amounts previously paid 708,334
Shares issued in connection with acquisition 12,091,142 9,374,455
Cash paid for income taxes $ 48,222